Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Assets (2022 - 2025)

Historic Current Assets for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $338.3 million.

  • Entrada Therapeutics' Current Assets fell 2730.89% to $338.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.3 million, marking a year-over-year decrease of 2730.89%. This contributed to the annual value of $440.0 million for FY2024, which is 1900.31% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Current Assets of $338.3 million as of Q3 2025, which was down 2730.89% from $369.1 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Current Assets high stood at $489.5 million for Q2 2024, and its period low was $209.9 million during Q4 2022.
  • In the last 4 years, Entrada Therapeutics' Current Assets had a median value of $383.0 million in 2023 and averaged $364.5 million.
  • Per our database at Business Quant, Entrada Therapeutics' Current Assets soared by 7618.63% in 2023 and then plummeted by 2730.89% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Current Assets (Quarter) stood at $209.9 million in 2022, then soared by 76.19% to $369.8 million in 2023, then grew by 19.0% to $440.0 million in 2024, then fell by 23.13% to $338.3 million in 2025.
  • Its Current Assets stands at $338.3 million for Q3 2025, versus $369.1 million for Q2 2025 and $403.2 million for Q1 2025.